Med. Pro Praxi 2004; 1: 51-52

C-reaktivní protein a infarkt myokardu

MUDr. Marcela Škvařilová Ph.D, MUDr. Mgr. Alan Bulava, prof. MUDr. Jan Lukl CSc
I. interní klinika FN a LF UP Olomouc

Keywords: C-reaktivní protein, ateroskleróza, rizikový faktor.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škvařilová M, Bulava A, Lukl J. C-reaktivní protein a infarkt myokardu. Med. praxi. 2004;2(1):51-52.

Kardiovaskulární nemoci jsou s současné době stále ještě nejčastější příčinou úmrtí ve vyspělých státech. Příčiny aterosklerózy jsou jednoznačně multifaktoriální, přesto je všeobecně již akceptován názor, že zánět ve sklerotickém plátu napomáhá k iniciaci a progresi aterosklerózy. I když se naše znalosti o patogeneze a léčbě aterosklerózy zvyšují exponenciálně, ještě stále více než u 50 % postižených nemocných nenajdeme tradiční rizikové faktory, jako je arteriální hypertenze, kouření, pozitivní rodinná anamnéza, obezita nebo hypercholesterolémie. Pozornost se proto zaměřuje na nové markery aterosklerózy, jako je C-reaktivní protein(CRP), který se zdá být nejvýznamnějším. Zánětlivá reakce v koronárním plátu hraje klíčovou úlohu v patogenezi aterotrombotické komplikace.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Duplaa C, Couffinhal T, Labat L, et al. Monocyte/macrophage recruitment end expression of endotelial adhesion proteins in human atherosclerotic lesions. Atherosclerosis 1996; 121: 253-266. Go to original source... Go to PubMed...
    2. Kuneš P, Krejsek J. C reaktivní protein a reakce akutní fáze. Cor et Vasa 2002;44(11): 467-475.
    3. Torzewski M, Rist C, Mortensen RD. C-reactive protein in the arterial intima. Role of C-reactive protein receptor-dependent monocyte recruiment in atherogenesis. Arterioscel Thromb Vas Biol 2000; 20: 2094-2099. Go to original source... Go to PubMed...
    4. Ridker PM, Buring J E, Shih H, et al. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determing risk of first myocardial infarction. Circulation 1997; 96: 4219-4225.
    5. Ridker PM, Kusdin R, Stampfer MJ, et al. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-2799. Go to original source... Go to PubMed...
    6. Fryer RH, Schowbe EP, Woods ML, et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J. Investing Med 1997; 45: 168-174.
    7. Fejfar Z, Přerovský I. Klinická fyziologie krevního oběhu, Galen 2002, str. 57.
    8. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a senzitive marker of imlammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-242. Go to original source... Go to PubMed...
    9. Ridker PM, Hennekens CH H, Buring J E, et al. C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women N Engl J Med 2000; (342)12: 836-843. Go to original source... Go to PubMed...
    10. Ridker P M, Hennekens CH, Buring J E, et al. IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus and Cytomegalovirus, and the risk for cardiovascular disease in women. Ann Intern Med 1999; 131:573-577. Go to original source... Go to PubMed...
    11. Folsom AR, Pankov JS, Tracy Rp, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol 2001; 88: 112-117. Go to original source... Go to PubMed...
    12. Veselka J, Procházková Š, Duchoňová R, et al. Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patient with stable angina pectoris or a pathological exercise test. Coron Artery Dis 2002; 13: 151-154. Go to original source... Go to PubMed...
    13. Toss H, LindahlB, Siegnahm S, et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary heart disease. Circulation 1997; 96: 4204-4210. Go to original source... Go to PubMed...
    14. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and durin coronary intervention in refractery unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-1435. Go to original source...
    15. Heesche Ch, Hamm Ch W, Breummer J, et al. Predictive Value of C-reactive protein nad Troponin T in Patients With Unstable Angina: A Comparative Analysis, J Am Coll Cardiol 2000; 35: 1535-1542. Go to original source... Go to PubMed...
    16. De Winter RJ, Heyde GS, Koch KT, et al. The prognostic value of pre-procedural plasma of C-reactive protein in patient undergoimg elective coronary angioplasty. Eur Heart J 2002; 23: 960-966. Go to original source... Go to PubMed...
    17. Festa A, DxAgostino RJ, Howard G, et al. Chronic subclinical inflammation as part of insulin resistence syndrome: The Insulin Resistence Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47. Go to original source... Go to PubMed...
    18. Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45: 391-418.
    19. Pasceri V, Willerson JT, Yeh ET, et al. Direct proinflamatory effect of C-reactive protein in human endotelial cells. Circulation 2000; 102: 2165-2168. Go to original source... Go to PubMed...
    20. Ridker PM, Rifai A, Pffefer MA, et al. For the Cholesterol and Recurrent Events (CARE) Invetogators. Long-term effects of pravastatin and plasma contentration of C-reactive protein. Circulation 1999; 100: 230-235. Go to original source... Go to PubMed...
    21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22. Go to original source... Go to PubMed...
    22. Ridker PM. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C reactive-protein evaulation. Curr Card Rep. 2000; 101: 1767-1772. Go to original source... Go to PubMed...
    23. Downs JR, Clearfield M, Weis S et al: Primary prevention of acute coronary events in men and women with average cholesterol levels: result of AFCAPS/ TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622. Go to original source... Go to PubMed...
    24. Zwaka TP,Hombach V, Torzewski J. C-reactive protein mediated low density lipoprotein uptake by macrophages. Implications for atheroscelrosis. Circulation 200; 103: 1194-1197. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.